Dopamine could potentially treat Alzheimer’s by stimulating the production of an enzyme that breaks down beta-amyloid plaques, researchers say. Qi Yang/Getty Images When beta-amyloid plaques form, ...

Alzheimer’s disease has been considered something that happens from within, generally speaking — but for the first time, researchers have identified cases that were triggered by a specific medical ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s ...

Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.

Alzheimer’s disease has been considered something that happens from within, generally speaking — but for the first time, researchers have identified cases that were triggered by a specific medical ...

Although 2016 ended with the failure of yet another antiamyloid agent for Alzheimer's disease (AD), the field is pushing ahead in 2017. The majority of late-phase clinical trials continue to address ...

As the investigators in that trial concluded, “The long-term implications of these findings are unknown and may be assessed in longer-term follow-up and in the phase 3 study (Clarity-AD).” The ...

Amyloid-beta-targeted monoclonal antibodies had negligible effects for adults with mild cognitive impairment or AD-related dementia.